Tests pre-surgery nutrition drink effects in people having bladder removal
Compares an oral nutrition supplement before surgery with usual care in adults removing the bladder.
Plain-language title generated from the registry record
Registry title: The Role of Preoperative Immunonutrition on Morbidity and Immune Response After Cystectomy (INCyst Trial)
Key facts
- Where
- Bern, Geneva, Lausanne, and Rennaz, SwitzerlandSee the 4 sites
- Phase
- Phase 3
Where in Switzerland
- University Hospital of BernBern, SwitzerlandTaking people
- University Hospital of GenevaGeneva, SwitzerlandTaking people
- Centre Hospitalier Universitaire Vaudois (CHUV)Lausanne, SwitzerlandTaking people
- Hospital of Riviera-ChablaisRennaz, SwitzerlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre Hospitalier Universitaire Vaudois
- Trial code
- NCT05726786
- Record updated
- 9 December 2025
- Original description
The goal of this clinical trial research study is to evaluate the impact of preoperative oral immunonutrition (IN) on post-operative complications in patients undergoing a cystectomy.Read full original descriptionShow less
The Role of Preoperative Immunonutrition on Morbidity and Immune Response After Cystectomy - A Multicenter Randomized Controlled Trial (INCyst Trial)
The goal of this clinical trial research study is to evaluate the impact of preoperative oral immunonutrition (IN) on post-operative complications in patients undergoing a cystectomy.
As a secondary focus, this study will aim to develop a signature that would identify patients that would benefit the most from IN.
This is a multicentric (Swiss: N=3), prospective, controlled, pragmatic, parallel-group comparative study with block randomization stratified by centers.
Inclusion: Patient undergoing open cystectomy (for all reasons); Age ≥18 years; Ability and willingness to provide informed consent documented by signature.
Exclusion: Current treatment with any immunosuppressive drug; In standard practice, pregnant or lactating women are systematically rejected by the surgeon for this surgical procedure. Furthermore, during the pre-surgical anaesthesia consultation, the eligibility of each patient for anaesthesia will be assessed according to the usual criteria and recommendations of the anaesthesia service of the CHUV; Other clinically significant concomitant disease affecting immunity (e.g., severe renal failure, HIV, SLE, transplant recipient, ...); Participation in another study with investigational drug within the 30 days preceding and during the present study; Previous enrolment into the current study; Emergency procedure (less than 7 days between screening and surgery); Contraindications to IN, e.g. known hypersensitivity or allergy to lactose, fish oil or soy lecithin; Inability to follow the procedures of the study, e.g. due psychological disorders, dementia, etc; Severe diarrhoea requiring medical attention; Use of IN independently of the study; Enrolment of the investigator, his/her family members, employees and other dependent persons.